GLP-1

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

DDW Highlights: 14 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Eli… Read More

#Podcasts

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

This week in Drug Discovery (6 – 10 April) 

News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW.  This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Lilly has made the headlines for both an approved drug and a drug collaboration.  The top stories: … Read More

#News

Pills
#Eli Lilly #FDA #GLP-1 #Obesity #Weight loss

FDA approves Lilly’s GLP-1 pill for weight loss

The US Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems.   "People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water… Read More

#News #Regulatory #Trending News

#ABPI #Clinical trials #GLP-1 #Immune response #NHS #Obesity #Oncology #Prostate cancer #T cell #Texas A&M University Health Science Center #Weight loss

DDW Highlights: 31 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates the key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a study found obesity could be treated in other ways than through drugs… Read More

#Podcasts

#ABPI #Clinical trials #Dementia #GLP-1 #Immune response #Neuroscience #NHS #Obesity #Oncology #Prostate cancer #T cell #Texas A&M University Health Science Center #Tregs #Weight loss

This week in Drug Discovery (23 – 27 March) 

News round-up for 23 – 27 March by Bruno Quinney, Content Team at DDW.  This week, obesity could be treated in other ways than through drugs suppressing appetite. Elsewhere, prostate cancer has been a central theme in cancer research.   The top stories:    Obesity… Read More

#News

#GLP-1 #Obesity #Weight loss

Obesity could be treated without suppressing appetite 

Obesity could be treated in other ways than using drugs suppressing appetite, a study reveals.  Researchers identified how brown fat cells, which are linked to weight loss, communicate to expand nerve and blood vessel networks, boosting heat generation. The findings, published in Nature Communications, hint at new ways… Read More

#News

Obese man measures his waist
#Diabetes #Eli Lilly #GLP-1 #Obesity #Phase III trial

Lilly’s triple agonist significantly reduces A1C and weight

Eli Lilly has announced positive topline results from TRANSCEND-T2D-1, a Phase III clinical trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise.   The trial enrolled adults diagnosed with type 2… Read More

#News

Novo Nordisk head office
#Adverse event #FDA #GLP-1 #Novo Nordisk #Obesity #Ozempic

Novo receives FDA warning, strikes deal with Hims & Hers

Novo Nordisk has received a Warning Letter from the US Food and Drug Administration (FDA) related to violations of postmarketing adverse drug experience (PADE) regulations.  The letter relates to an inspection that took place in early 2025, in which the FDA found serious violations of PADE reporting requirements, in response… Read More

#Business & Investment #News #Regulatory #Trending News

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #GLP-1 #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Obesity #Prostate cancer #UK #ViiV Healthcare #Weight loss

This week in Drug Discovery (23 – 27 February) 

News round-up for 23 – 27 February by Bruno Quinney, Content Team at DDW.  This week in drug discovery, more effective treatments have been found for both HIV and chronic wounds. Elsewhere, €40,000 is up for grabs in prostate cancer research.  The top stories:   … Read More

#News

#Biomarkers #Genetics #GLP-1 #Weight loss

Genetic markers could predict GLP-1 efficacy, data shows 

Genetic biomarkers could predict GLP-1 efficacy response, results show.  Human omics company Ovation.io and precision medicine company PrecisionLife have released findings from the first phase of their collaboration, showing biomarkers can predict the efficacy, safety and tolerability of GLP-1 therapies.  Using Ovation’s longitudinal clinical and… Read More

#News

Woman standing on scales
#Biopharmaceutical #Clinical trial #GLP-1 #Weight loss

Verdiva Bio completes enrolment for oral GLP-1 trial 

Biopharmaceutical company Verdiva Bio has completed its participant enrolment for the Phase IIb study of its once-weekly oral GLP-1.  VRB-101 is a once-weekly oral, cAMP-biased, GLP-1 peptide analogue candidate for body weight reduction in people with overweight or obesity.  The Phase IIb EVOLVE-2 trial is randomised, double-blind… Read More

#News

Scales showing a comparison between Mounjaro and Ozempic
#GLP-1 #Novo Nordisk #Obesity #Weight loss

Head-to-head obesity trial disappointment for Novo Nordisk 

Novo Nordisk has seen a significant fall in its stock value following disappointing trial results for its obesity treatment CagriSema, which is a fixed dose combination of cagrilintide 2.4mg and semaglutide 2.4mg.  Although CagriSema demonstrated 23% weight loss in the open-label head-to-head Phase III REDEFINE 4 trial,… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Antibodies #Biotech #Drug discovery #GLP-1 #IPO #Mergers and acquisitions #Neuroscience

JPM 2026: Less talk and more action 

‘JPM 2026’ certainly felt different to recent editions of the conference. The sky was blue – and the XBI had nearly doubled over the previous nine months.  There’s nothing like a little winter sun and booming stocks to put a spring in an executive’s step!  But questions over the robustness of the biopharma sector remain – to be expected after… Read More

#Exclusive Content

#Breast cancer #Cell therapy #Clinical trial #GLP-1 #Huntington's disease #LoQus23 Therapeutics #Metabolic diseases #Obesity #Osteoarthritis #Ozempic #Phesi #RNAi #Scarcell Therapeutics #Weight loss

DDW Highlights: 13 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a new report found breast cancer was the world’s most studied disease… Read More

#Podcasts

#Breast cancer #Cell therapy #Clinical trial #GLP-1 #Huntington's disease #LoQus23 Therapeutics #Metabolic diseases #Obesity #Osteoarthritis #Ozempic #Phesi #RNAi #Scarcell Therapeutics #Weight loss

This week in Drug Discovery (5 – 9 January) 

News round-up for 5 – 9 January by Bruno Quinney, Content Team at DDW.  This week in DDW, a new report finds breast cancer is the world’s most studied disease for the fifth year running. That same report predicts obesity to break into the top five, with weight loss a key theme across… Read More

#News